Acuitas Therapeutics

Vancouver, BC
Find alternatives to Acuitas Therapeutics for mRNA →
Reagent / Material Supplier
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
56.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (11) ○ EMA GMP ○ MHRA GMP

Quick Facts: Acuitas Therapeutics

Signal Score
56.5/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Vancouver, BC
Modalities
mRNA
Active Programs
No ClinicalTrials.gov matches confirmed — 6 partnership signals in press (announcements, not verified)
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Acuitas Therapeutics

Reagent/raw material supplier.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 6 partnership announcements found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesmRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 53.0
1 manufacturing site: Vancouver, BC
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Vancouver, BC
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals11 articles (not scored)
1 manufacturing site: Vancouver, BC
Modalities: mRNA
Capacity assessment: 53.0/100

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Company Signals 11 articles

Company announcements, not verified evidence. They do not change any score.
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com Nigeria
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com Nigeria
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com South Africa
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com South Africa
partnership 2026-04-20
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy - TipRanks
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy  TipRanks
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech - Investing.com
Genflow partners with Acuitas for gene therapy delivery tech  Investing.com
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com Australia
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com Australia
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com UK
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com UK
general 2026-04-16
Circio and Acuitas partner on circular RNA CAR T therapy - Drug Target Review
Circio and Acuitas partner on circular RNA CAR T therapy  Drug Target Review
general 2026-04-15
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics - TradingView — Track All Markets
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics  TradingView
general 2026-04-15
Circio, Acuitas Therapeutics to Evaluate In-vivo CAR-T Cell Therapy Technology - marketscreener.com
Circio, Acuitas Therapeutics to Evaluate In-vivo CAR-T Cell Therapy Technology  marketscreener.com
general 2026-04-15
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics - Finansavisen
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics  Finansavisen
general 2026-04-15
Circio Holding ASA And Acuitas Therapeutics Enter In Vivo Car-T Cell Therapy Evaluation Agreement - marketscreener.com
Circio Holding ASA And Acuitas Therapeutics Enter In Vivo Car-T Cell Therapy Evaluation Agreement  marketscreener.com

Frequently Asked Questions About Acuitas Therapeutics

What is Acuitas Therapeutics's CDMO Signal Score?
Acuitas Therapeutics has a Signal Score of 56/100, based on quality, operations, financial stability, and capacity data.
Evaluating Acuitas Therapeutics for a manufacturing program?
Use the free AI matchmaker to compare Acuitas Therapeutics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

Evonik Health Care
Birmingham, AL · Vancouver, BC
Signal Score: 81.5
mRNA, Biologics
Precision NanoSystems (Cytiva)
Vancouver, BC, Canada
Signal Score: 60.5
mRNA
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics

Compare Acuitas Therapeutics with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Acuitas Therapeutics
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.